- BeyondSpring Inc BYSI has submitted marketing applications in the U.S. and China seeking approval for plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN).
- Neutropenia is a condition wherein a person has a low level of neutrophils, a white blood cell that helps the body fight infection.
- The submission is based on data from PROTECTIVE-2 Phase 3 study, which showed that plinabulin combined with pegfilgrastim demonstrated superior CIN prevention benefit compared to pegfilgrastim alone.
- The study met the primary endpoint, with a statistically significant improvement in the rate of prevention of grade 4 neutropenia (improved from 13.6% to 31.5%).
- Price Action: BYSI shares are up 4.1% higher at $11.07 in the premarket trading on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
